These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 32880785)

  • 61. The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements.
    Suurmeijer AJ; Dickson BC; Swanson D; Zhang L; Sung YS; Huang HY; Fletcher CD; Antonescu CR
    Genes Chromosomes Cancer; 2019 Nov; 58(11):739-746. PubMed ID: 31112350
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
    Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
    Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
    Bell D; Ferrarotto R; Liang L; Goepfert RP; Li J; Ning J; Broaddus R; Weber RS; El-Naggar AK
    Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 66. Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.
    Musholt TJ; Schönefeld S; Schwarz CH; Watzka FM; Musholt PB; Fottner C; Weber MM; Springer E; Schad A
    Langenbecks Arch Surg; 2010 Sep; 395(7):877-83. PubMed ID: 20640859
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 70. GISTs with
    Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.
    Arndt A; Steinestel K; Rump A; Sroya M; Bogdanova T; Kovgan L; Port M; Abend M; Eder S
    J Pathol Clin Res; 2018 Jul; 4(3):175-183. PubMed ID: 29633575
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis.
    Okubo Y; Toda S; Kadoya M; Sato S; Yoshioka E; Hasegawa C; Ono K; Washimi K; Yokose T; Miyagi Y; Masudo K; Iwasaki H; Hayashi H
    Virchows Arch; 2024 Sep; 485(3):509-518. PubMed ID: 38472412
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer.
    Conde E; Hernandez S; Sanchez E; Regojo RM; Camacho C; Alonso M; Martinez R; Lopez-Rios F
    Arch Pathol Lab Med; 2021 Aug; 145(8):1031-1040. PubMed ID: 33112951
    [TBL] [Abstract][Full Text] [Related]  

  • 74. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer.
    Leeman-Neill RJ; Kelly LM; Liu P; Brenner AV; Little MP; Bogdanova TI; Evdokimova VN; Hatch M; Zurnadzy LY; Nikiforova MN; Yue NJ; Zhang M; Mabuchi K; Tronko MD; Nikiforov YE
    Cancer; 2014 Mar; 120(6):799-807. PubMed ID: 24327398
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
    Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Case Report: Identification of a novel
    Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
    Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
    [No Abstract]   [Full Text] [Related]  

  • 78. GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland.
    Nikiforova MN; Nikitski AV; Panebianco F; Kaya C; Yip L; Williams M; Chiosea SI; Seethala RR; Roy S; Condello V; Santana-Santos L; Wald AI; Carty SE; Ferris RL; El-Naggar AK; Nikiforov YE
    Thyroid; 2019 Feb; 29(2):161-173. PubMed ID: 30648929
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
    Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
    J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
    [TBL] [Abstract][Full Text] [Related]  

  • 80. S100 and Pan-Trk Staining to Report NTRK Fusion-Positive Uterine Sarcoma: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
    Chiang S
    Int J Gynecol Pathol; 2021 Jan; 40(1):24-27. PubMed ID: 33290352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.